JP2017169559A5 - - Google Patents

Download PDF

Info

Publication number
JP2017169559A5
JP2017169559A5 JP2017037848A JP2017037848A JP2017169559A5 JP 2017169559 A5 JP2017169559 A5 JP 2017169559A5 JP 2017037848 A JP2017037848 A JP 2017037848A JP 2017037848 A JP2017037848 A JP 2017037848A JP 2017169559 A5 JP2017169559 A5 JP 2017169559A5
Authority
JP
Japan
Prior art keywords
antibody
seq
cell
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017037848A
Other languages
English (en)
Japanese (ja)
Other versions
JP6334763B6 (ja
JP6334763B2 (ja
JP2017169559A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017169559A publication Critical patent/JP2017169559A/ja
Publication of JP2017169559A5 publication Critical patent/JP2017169559A5/ja
Application granted granted Critical
Publication of JP6334763B2 publication Critical patent/JP6334763B2/ja
Publication of JP6334763B6 publication Critical patent/JP6334763B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017037848A 2011-06-02 2017-03-01 Fcレセプター結合タンパク質 Active JP6334763B6 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161492617P 2011-06-02 2011-06-02
US61/492,617 2011-06-02
US201161498266P 2011-06-17 2011-06-17
US61/498,266 2011-06-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014513732A Division JP6104897B2 (ja) 2011-06-02 2012-06-01 Fcレセプター結合タンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018085040A Division JP6638018B2 (ja) 2011-06-02 2018-04-26 Fcレセプター結合タンパク質

Publications (4)

Publication Number Publication Date
JP2017169559A JP2017169559A (ja) 2017-09-28
JP2017169559A5 true JP2017169559A5 (cg-RX-API-DMAC7.html) 2017-12-07
JP6334763B2 JP6334763B2 (ja) 2018-05-30
JP6334763B6 JP6334763B6 (ja) 2018-07-11

Family

ID=47259886

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014513732A Active JP6104897B2 (ja) 2011-06-02 2012-06-01 Fcレセプター結合タンパク質
JP2017037848A Active JP6334763B6 (ja) 2011-06-02 2017-03-01 Fcレセプター結合タンパク質
JP2018085040A Active JP6638018B2 (ja) 2011-06-02 2018-04-26 Fcレセプター結合タンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014513732A Active JP6104897B2 (ja) 2011-06-02 2012-06-01 Fcレセプター結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018085040A Active JP6638018B2 (ja) 2011-06-02 2018-04-26 Fcレセプター結合タンパク質

Country Status (14)

Country Link
US (6) US9359438B2 (cg-RX-API-DMAC7.html)
EP (2) EP2714084B1 (cg-RX-API-DMAC7.html)
JP (3) JP6104897B2 (cg-RX-API-DMAC7.html)
KR (1) KR102014554B1 (cg-RX-API-DMAC7.html)
CN (2) CN105622754B (cg-RX-API-DMAC7.html)
AU (2) AU2012262007B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013030352B1 (cg-RX-API-DMAC7.html)
CA (1) CA2837527C (cg-RX-API-DMAC7.html)
ES (1) ES2748583T3 (cg-RX-API-DMAC7.html)
IL (1) IL229618B (cg-RX-API-DMAC7.html)
MX (1) MX343659B (cg-RX-API-DMAC7.html)
PH (1) PH12013502378A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201604493TA (cg-RX-API-DMAC7.html)
WO (1) WO2012167039A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI593423B (zh) * 2008-04-25 2017-08-01 戴埃克斯有限公司 Fc受體結合蛋白
SG10201604493TA (en) 2011-06-02 2016-07-28 Dyax Corp Fc RECEPTOR BINDING PROTEINS
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
JP6620094B2 (ja) 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 免疫応答を調節するための組成物および方法
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
CN118667014A (zh) * 2015-01-30 2024-09-20 动量制药公司 Fcrn抗体及其使用方法
US10822417B2 (en) * 2016-04-25 2020-11-03 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
EP4282487A3 (en) * 2016-07-29 2024-02-14 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
KR20190089941A (ko) 2016-12-01 2019-07-31 사빅 글로벌 테크놀러지스 비.브이. 하이브리드 복합 뒷문
RU2020100880A (ru) * 2017-06-15 2021-07-15 Юсб Биофарма Срл Способ лечения иммунной тромбоцитопении
AU2018380979B2 (en) 2017-12-08 2023-07-20 argenx BV Use of FcRn antagonists for treatment of generalized myasthenia gravis
SG11202005021PA (en) 2017-12-13 2020-07-29 Momenta Pharmaceuticals Inc Fcrn antibodies and methods of use thereof
BR112020025001A2 (pt) 2018-06-08 2021-03-23 Argenx Bvba composições e métodos para o tratamento da trombocitopenia imune
MX2021000788A (es) * 2018-07-20 2021-07-21 Momenta Pharmaceuticals Inc Composiciones de anticuerpos del receptor de fc (fcrn).
US20230287107A1 (en) * 2019-07-23 2023-09-14 Shanghaitech University Asic1 channel antagonist antibody
TW202140552A (zh) 2020-01-08 2021-11-01 比利時商阿根思公司 用於治療天皰瘡病症的方法
CA3183153A1 (en) 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
AU2023291783A1 (en) 2022-06-15 2024-12-12 argenx BV Fcrn binding molecules and methods of use
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588A (zh) * 2024-10-17 2025-02-21 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3875456T3 (de) 1987-11-09 1998-06-10 Becton Dickinson Co Verfahren zur Analyse hämatopoietischer Zellen in einer Probe.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
PT1712623E (pt) 1997-01-21 2011-12-21 Gen Hospital Corp Selecção de proteínas utilizando fusões de arn-proteína
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
DE60333554D1 (de) 2002-03-04 2010-09-09 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
JP2007501847A (ja) * 2003-08-08 2007-02-01 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己/同種免疫状態の治療用抗FcRn抗体
WO2006118772A2 (en) 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
WO2007087289A2 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
US20070181136A1 (en) 2006-02-08 2007-08-09 Gelb Michael L Oral appliance
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
TWI593423B (zh) 2008-04-25 2017-08-01 戴埃克斯有限公司 Fc受體結合蛋白
US8537763B2 (en) 2008-06-30 2013-09-17 Motorola Mobility Llc Frame allocation to support legacy wireless communication protocols on uplink transmission
EP2322610B1 (en) * 2008-07-16 2016-12-14 Medical and Biological Laboratories Co., Ltd. Anti-human clcp1 antibody and use thereof
TW201029662A (en) * 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
SG10201604493TA (en) 2011-06-02 2016-07-28 Dyax Corp Fc RECEPTOR BINDING PROTEINS
AU2018281045A1 (en) 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
BR112020025001A2 (pt) 2018-06-08 2021-03-23 Argenx Bvba composições e métodos para o tratamento da trombocitopenia imune

Similar Documents

Publication Publication Date Title
JP2017169559A5 (cg-RX-API-DMAC7.html)
US20230242651A1 (en) Stable antibody variable domain framework combinations
JP2020519308A5 (cg-RX-API-DMAC7.html)
JP2020508655A5 (cg-RX-API-DMAC7.html)
JP2020504101A5 (cg-RX-API-DMAC7.html)
KR102286053B1 (ko) 신규한 항체 기본구조
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
HRP20201993T1 (hr) Protutijela protiv pd-1
US11319371B2 (en) Anti-CD3 antibodies
RU2011153932A (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Toll-ПОДОБНЫМ РЕЦЕПТОРАМ 2 И ИХ ПРИМЕНЕНИЯ
FI3561057T3 (fi) Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
JP2019504617A5 (cg-RX-API-DMAC7.html)
FI3310812T3 (fi) Anti-her2-vasta-aineita ja käyttömenetelmiä
JP2020524510A5 (cg-RX-API-DMAC7.html)
JP2012514997A5 (cg-RX-API-DMAC7.html)
RU2013119957A (ru) Человеческие антитела к онкостатину м и способы их применения
RU2012122203A (ru) Композиции и способы для лечения восполительных нарушений
WO2023193732A1 (zh) 一种抗ccr8抗体或其抗原结合片段
JP2016518333A5 (cg-RX-API-DMAC7.html)
CN116940598A (zh) 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
JP2022528387A (ja) アビド結合多重特異性抗体を作製する方法
FI4031569T3 (fi) Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät
US20150093783A1 (en) Humanized antibodies to ca215
JP2016540504A5 (cg-RX-API-DMAC7.html)
RU2017115201A (ru) Моноклональное антитело, подавляющее иммуносуспрессорные функции патогенов, антиген-связывающий фрагмент указанного антитела и гибридомы, вырабатывающие указанное антитело